Cargando…

Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition

The 26S proteasome inhibitor bortezomib is currently used to treat multiple myeloma but also is effective in the treatment of antibody-mediated autoimmune disorders. One clinical concern is bortezomib’s toxicity towards the (central) nervous system. We used standardized neuropsychological testing to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huehnchen, Petra, Springer, Andreas, Kern, Johannes, Kopp, Ute, Kohler, Siegfried, Alexander, Tobias, Hiepe, Falk, Meisel, Andreas, Boehmerle, Wolfgang, Endres, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425526/ https://www.ncbi.nlm.nih.gov/pubmed/32954282 http://dx.doi.org/10.1093/braincomms/fcaa021

Ejemplares similares

Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice
por: Boehmerle, Wolfgang, et al.
Publicado: (2014)

Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial
por: Kohler, Siegfried, et al.
Publicado: (2019)

Assessment of Paclitaxel Induced Sensory Polyneuropathy with “Catwalk” Automated Gait Analysis in Mice
por: Huehnchen, Petra, et al.
Publicado: (2013)

Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy
por: Huehnchen, Petra, et al.
Publicado: (2018)

Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice
por: Huehnchen, Petra, et al.
Publicado: (2020)

Focal brain ischemia in mice does not cause electrophysiological signs of critical illness neuropathy
por: Huehnchen, Petra, et al.
Publicado: (2020)

A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL/6 mice
por: Huehnchen, P, et al.
Publicado: (2017)

Induced pluripotent stem cell-derived brain organoids as potential human model system for chemotherapy induced CNS toxicity
por: Scholz, Sophie, et al.
Publicado: (2022)

Suramin-Induced Neurotoxicity: Preclinical Models and Neuroprotective Strategies
por: von der Ahe, David, et al.
Publicado: (2018)

Dataset for: Modeling chemotherapy induced neurotoxicity with human induced pluripotent stem cell (iPSC)-derived sensory neurons
por: Schinke, Christian, et al.
Publicado: (2021)

Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice
por: Khodadadi, Laleh, et al.
Publicado: (2015)

Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy
por: Huehnchen, Petra, et al.
Publicado: (2022)

Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events
por: Müller-Jensen, Leonie, et al.
Publicado: (2023)

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
por: Alexander, Tobias, et al.
Publicado: (2015)

Salinomycin induces calpain and cytochrome c-mediated neuronal cell death
por: Boehmerle, W, et al.
Publicado: (2011)

“You Shall Not Pass”—tight junctions of the blood brain barrier
por: Bauer, Hans-Christian, et al.
Publicado: (2014)

Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial – Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial
por: Huehnchen, Petra, et al.
Publicado: (2022)

An easier way to pass the Coulomb barrier
por: Turko, L
Publicado: (1989)

Therapeutic inhibition of proteasomes in systemic lupus erythematosus
por: Hiepe, Falk, et al.
Publicado: (2011)

The Maintenance of Memory Plasma Cells
por: Khodadadi, Laleh, et al.
Publicado: (2019)

Virus strategies for passing the nuclear envelope barrier
por: Kobiler, Oren, et al.
Publicado: (2012)

Leaky barriers: leaky enough for fish to pass?
por: Müller, Stephanie, et al.
Publicado: (2021)

Magnetic Nanoparticles Interact and Pass an In Vitro Co-Culture Blood-Placenta Barrier Model †
por: Müller, Elena K., et al.
Publicado: (2018)

Calprotectin as potential novel biomarker in myasthenia gravis
por: Stascheit, Frauke, et al.
Publicado: (2021)

Physical activity and environmental enrichment regulate the generation of neural precursors in the adult mouse substantia nigra in a dopamine-dependent manner
por: Klaissle, Philipp, et al.
Publicado: (2012)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Fatigue in myasthenia gravis: risk factors and impact on quality of life
por: Hoffmann, Sarah, et al.
Publicado: (2016)

ON THE SIZE OF THE TOXIC PARTICLE PASSING THE INTESTINAL BARRIER IN BOTULISM
por: Heckly, Robert J., et al.
Publicado: (1960)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE
por: Burns, Marie, et al.
Publicado: (2021)

To Pass or Not To Pass: Predicting the Blood–Brain Barrier Permeability with the 3D-RISM-KH Molecular Solvation Theory
por: Roy, Dipankar, et al.
Publicado: (2019)

Intravenously Administered Anti-recoverin Antibody Alone Does Not Pass through the Blood-Retinal Barrier
por: Kim, Jeong Hun, et al.
Publicado: (2011)

Peripheral Routes to Neurodegeneration: Passing Through the Blood–Brain Barrier
por: Giannoni, Patrizia, et al.
Publicado: (2020)

You shall not pass! A Chromatin barrier story in plants
por: Velay, Florent, et al.
Publicado: (2022)

Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway
por: Salih, Farid, et al.
Publicado: (2022)

Présent passé, passé présent
por: Ionesco, Eugène
Publicado: (1968)

Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma
por: Li, Xuesong, et al.
Publicado: (2020)

PB2079: LACTATE DECREASES BORTEZOMIB SENSITIVITY AND PREDICTS POOR CLINICAL OUTCOMES OF MULTIPLE MYELOMA
por: MA, Naya, et al.
Publicado: (2023)

Passing of Nanocarriers across the Histohematic Barriers: Current Approaches for Tumor Theranostics
por: Gareev, Kamil, et al.
Publicado: (2023)

Cell-Specific Type I IFN Signatures in Autoimmunity and Viral Infection: What Makes the Difference?
por: Kyogoku, Chieko, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9vb2lc3f1pnm6c4dq0sncosd7i